ArticleBMC infectious diseases2025
A retrospective study on the association between ABO blood group and the severity and prognosis of hospitalized Chinese patients with COVID-19.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of ABO/Rh Blood Groups and ABO Gene VariantsViruses · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe outbreak of the novel coronavirus (SARS-CoV-2) has led to a severe public health crisis worldwide, significantly impacting human lives and health. The clinical manifestations and severity of COVID-19 vary among individuals, influenced by factors such as lifestyle, underlying health conditions, and genetic predispositions. Among these factors, blood type has garnered considerable attention as a potential biological marker that may affect both the risk of SARS-CoV-2 infection and disease severity.
methodsThis retrospective study analyzed hospitalized COVID-19 patients at Fujian Medical University First Hospital from December 1, 2022, to January 31, 2023. Epidemiological information, clinical data, admission classification, ABO blood type, laboratory results, and clinical outcomes were extracted. Univariate analysis was used to compare clinical profiles and risk factors across blood types.
resultsA total of 823 patients (516 males, 307 females) were included. The results showed that Patients with mild/moderate disease at admission exhibited significantly higher cure rates, lower mortality, reduced pneumonia incidence, and younger age compared to severe/critical cases (P < 0.05). Furthermore, Forty-four laboratory indicators—including liver function, renal function, and coagulation parameters—showed significant intergroup differences. Notably, type B blood was associated with a reduced risk of progression to severe/critical disease (P < 0.05), though no significant correlation was observed between blood type and ultimate prognosis.
conclusionNon-B blood types were associated with increased risks of severe/critical COVID-19 progression. Integrating ABO blood typing with clinical laboratory data may improve risk prediction for COVID-19 patients. These findings suggest that ABO blood type could serve as a predictive biomarker for SARS-CoV-2 infection severity. However, further mechanistic studies are required to elucidate the relationship between blood type and disease pathogenesis. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.